



## **New Drug Approval for Eyprotor<sup>R</sup> (Protein-free Calf Blood Extract Eye-gel) in China**

(Hong Kong, 13 May 2008) – Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: [www.leespharm.com](http://www.leespharm.com)) today announced that the new drug application for the Group's in-house product~Eyprotor<sup>®</sup> ("Protein-free Calf Blood Extract Eye-gel") has been approved by the SFDA of China.

Eyprotor<sup>R</sup> is the fifth product developed in-house that have successfully obtained the marketing approval by China SFDA since 1997. Its approval further ascertains Leespharm's ability to move technology from benchside to bedside.

Eyprotor<sup>R</sup> contains active ingredients derived from calf red blood cell using the Group's proprietary and patented technology. It facilitates the healing of tissue without angiogenesis effect. It is indicated for patients with corneal epithelium abrasion. Results of clinical study have shown that Eyprotor<sup>®</sup> is well tolerated and effective in treatment of corneal abrasion. The comparative study demonstrated that Eyprotor<sup>®</sup> is not only as effective as "Human Recombinant Fibroblast Growth Factor (hrFGF) Eye Drops" in facilitating the healing of cornea ulcer, but also has much less angiogenesis effect than "hrFGF Eye Drops".

Cornea ulcer can be caused by abrasion, bacterial or viral infections and can lead to blindness if is not properly treated. It affects millions of people in China every year. The treatment option is still limited. With its effectiveness in promoting healing of tissue without angiogenesis effect, Eyprotor<sup>®</sup> is in position to fill an unmet need in the clinical setting.

"We're extremely excited for the approval of this new product and are particularly grateful for the hard work and tireless efforts of our research and development colleagues. I believe our Eyprotor<sup>®</sup> could be an exciting alternative for many of the corneal abrasion sufferers," stated Dr. Benjamin Li, the Chief Executive Officer of the Group. "The approval provides additional boost to the Group's growth momentum." The Group is expected to launch the product in third quarter, 2008 which will be the third launch of the Group in as many years.

### About Lee's

Lee's Pharmaceutical Holdings Limited is a Hong Kong listed (Stock code: 8221) biopharmaceutical company with over 13 years operation in China's pharmaceutical industry. It is a fully integrated with solid infrastructures in drug development, clinical development, regulatory and sales and marketing in China with global perspective and it currently markets five products in China. The Group focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology and gynecology with more than 10 products

under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US and European companies. For additional information about Lee's Pharm, please visit: [www.leespharm.com](http://www.leespharm.com).

**Safe Harbor Statement**

*The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*